BRTX BioRestorative Therapies, Inc. Stock Quote

BRTX [NASD]

Index	-	P/E	-	EPS (ttm)	-20.01	Insider Own	17.80%	Shs Outstand	3.52M	Perf Week	-0.59%
Market Cap	10.70M	Forward P/E	-	EPS next Y	-2.42	Insider Trans	100.48%	Shs Float	2.88M	Perf Month	-23.76%
Income	-33.50M	PEG	-	EPS next Q	-0.49	Inst Own	20.00%	Short Float	1.79%	Perf Quarter	-34.62%
Sales	0.05M	P/S	232.67	EPS this Y	-30.60%	Inst Trans	25.96%	Short Ratio	2.09	Perf Half Y	-17.40%
Book/sh	5.72	P/B	0.60	EPS next Y	-13.10%	ROA	-276.40%	Target Price	37.00	Perf Year	-85.26%
Cash/sh	6.17	P/C	0.55	EPS next 5Y	-	ROE	-405.20%	52W Range	2.75 - 32.00	Perf YTD	-21.21%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-89.12%	Beta	-
Dividend %	-	Quick Ratio	40.30	Sales past 5Y	-	Gross Margin	-	52W Low	26.55%	ATR	0.36
Employees	7	Current Ratio	40.30	Sales Q/Q	-70.60%	Oper. Margin	-	RSI (14)	45.17	Volatility	11.67% 9.62%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	93.60%	Profit Margin	-	Rel Volume	0.43	Prev Close	3.42
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	24.72K	Price	3.48
Recom	2.00	SMA20	-8.23%	SMA50	-11.48%	SMA200	-44.05%	Volume	10,045	Change	1.77%

Jun-30-22 07:30AM	BioRestorative Therapies Announces First Patient Enrolled for the Companys Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) GlobeNewswire -14.24%
Jun-22-22 07:30AM	BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Companys Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) GlobeNewswire -12.43%
07:00AM	EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study Benzinga
Jun-13-22 07:00AM	BioRestorative Therapies Announces Clinical Site Initiation for the Companys Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) GlobeNewswire -6.68%
Apr-29-22 08:00AM	BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease GlobeNewswire
Apr-18-22 08:00AM	BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease GlobeNewswire
Apr-04-22 08:00AM	BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification GlobeNewswire
Mar-10-22 08:00AM	BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program GlobeNewswire
Feb-16-22 08:30AM	BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program GlobeNewswire +13.65%
Feb-07-22 09:00AM	BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease Site Selection Underway GlobeNewswire
07:45AM	BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell GlobeNewswire
Feb-02-22 08:00AM	BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio GlobeNewswire -5.96%
Jan-26-22 06:00AM	BioRestorative Therapies Named One of Ten Most Innovative Regenerative Medicine Companies in 2022 by Insights Care Magazine GlobeNewswire
Jan-11-22 06:00AM	BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance GlobeNewswire +5.50%
Jan-06-22 06:00AM	BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference GlobeNewswire +8.56%
Jan-04-22 06:00AM	BioRestorative Therapies Awarded an STTR Phase I Grant to Explore the Therapeutic Effects of PEG-Peptide Hydrogel-Encapsulated Hypoxic Bone Marrow Stem Cells GlobeNewswire
Dec-22-21 07:28AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday InvestorPlace +17.51%
05:53AM	BioRestorative Stock Surges After Recruiting PRC Clinical As Partner For Lead Product Study Benzinga
Dec-21-21 04:01PM	BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease GlobeNewswire
06:00AM	BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show GlobeNewswire
Dec-20-21 06:00AM	BioRestorative Therapies, Inc. Releases Year-End Message GlobeNewswire
Dec-02-21 06:00AM	BioRestorative Therapies Announces Filing of Ten Patent Applications Related to its BRTX-100 Program GlobeNewswire
Nov-23-21 04:05PM	WISeKey, Luminaries21.com and OISTE.ORG Foundation signed a strategic agreement to launch high level NFTs for Good by WISe.ART with the support of 1090 worldwide leader members of Luminaries 21 GlobeNewswire
Nov-22-21 12:00PM	WISeKey Announces Full Year 2021 Revenue Guidance of $20 Million, an Increase of 32% as Compared to Full Year 2020 GlobeNewswire -9.93%
Nov-19-21 12:27PM	WISeKey Strengthens its Smart Card Reader Chips Business for Healthcare Applications and Renews Agreement with HID Global, an ASSA ABLOY Company GlobeNewswire
06:00AM	BioRestorative Therapies Enters into Letter of Intent with PRC Clinical GlobeNewswire
Nov-10-21 06:00AM	BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer GlobeNewswire
Nov-09-21 02:20PM	BioRestorative Therapies Announces Closing of $23 Million Public Offering GlobeNewswire +6.27%
Nov-04-21 09:21PM	BioRestorative Therapies Prices $23 Million Public Offering and Uplisting to the Nasdaq Capital Market GlobeNewswire
Oct-26-21 04:05PM	BioRestorative Therapies Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq GlobeNewswire -5.71%
08:00AM	BioRestorative Therapies Announces Nomination of Two New Members to the Board of Directors GlobeNewswire
Sep-23-21 09:00AM	BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program GlobeNewswire +9.23%
Sep-02-21 09:00AM	BioRestorative Therapies Receives Patent in Australia Related to its Off-the-Shelf ThermoStem® Program GlobeNewswire +31.25%
Aug-31-21 09:00AM	BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem® Program GlobeNewswire +6.58%
Aug-19-21 06:00AM	BioRestorative Therapies Awarded One of Top 10 Spine Device Companies by MedTech Outlook GlobeNewswire
Aug-11-21 08:30AM	BioRestorative Therapies Discusses Upcoming Annual Meeting of Stockholders GlobeNewswire
Aug-09-21 11:58AM	BioRestorative Therapies Announces Filing of Registration Statement for Proposed Public Offering GlobeNewswire +8.00%
Jun-07-21 07:00AM	CEO Presenting on the Emerging Growth Conference on June 9. Register here GlobeNewswire +13.92%

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ALSTODT LANCE	President, CEO, COB	Jun 30	Buy	3.10	1,100	3,408	182,021	Jul 01 09:20 AM
Broadrick Dale	10% Owner	Jun 21	Buy	3.68	100	368	295,473	Jun 23 03:42 PM
Broadrick Dale	10% Owner	Jun 17	Buy	3.80	600	2,282	295,373	Jun 23 03:42 PM
Broadrick Dale	10% Owner	Jun 16	Buy	3.81	2,000	7,611	294,773	Jun 17 05:05 PM
ALSTODT LANCE	President, CEO, COB	Jun 16	Buy	3.73	600	2,238	180,921	Jun 17 04:02 PM
Kristal Robert Eugene	Chief Financial Officer	Jun 15	Buy	3.61	194	700	7,994	Jun 15 05:50 PM
ALSTODT LANCE	President, CEO, COB	Jun 15	Buy	3.68	700	2,578	180,321	Jun 15 05:30 PM
Broadrick Dale	10% Owner	Jun 15	Buy	3.72	1,200	4,464	292,773	Jun 17 05:05 PM
ALSTODT LANCE	President, CEO, COB	Jun 14	Buy	3.91	500	1,956	179,621	Jun 15 11:01 AM
ALSTODT LANCE	President, CEO, COB	Jun 13	Buy	3.95	200	790	179,121	Jun 14 11:55 AM
Broadrick Dale	10% Owner	Jun 13	Buy	3.92	1,300	5,097	291,573	Jun 15 04:45 PM
Broadrick Dale	10% Owner	Jun 10	Buy	4.23	600	2,540	290,273	Jun 13 03:33 PM
Broadrick Dale	10% Owner	Jun 09	Buy	4.27	1,000	4,266	289,673	Jun 13 03:33 PM
ALSTODT LANCE	President, CEO, COB	Jun 08	Buy	4.28	100	428	178,921	Jun 09 11:41 AM
Broadrick Dale	10% Owner	Jun 08	Buy	4.33	2,400	10,395	288,673	Jun 09 04:42 PM
Kristal Robert Eugene	Chief Financial Officer	Jun 07	Buy	4.56	200	912	7,800	Jun 07 12:22 PM
Broadrick Dale	10% Owner	Jun 07	Buy	4.72	3,600	17,003	286,273	Jun 09 04:42 PM
Broadrick Dale	10% Owner	Jun 06	Buy	4.93	3,000	14,798	282,673	Jun 07 01:52 PM
Broadrick Dale	10% Owner	Jun 03	Buy	4.90	1,200	5,879	279,673	Jun 07 01:52 PM
Broadrick Dale	10% Owner	Jun 02	Buy	4.69	1,000	4,688	278,473	Jun 06 01:35 PM
Broadrick Dale	10% Owner	Jun 01	Buy	4.46	9,213	41,122	277,473	Jun 03 04:03 PM
ALSTODT LANCE	President, CEO, COB	Jun 01	Buy	4.60	200	920	178,821	Jun 03 06:58 AM
Broadrick Dale	10% Owner	May 27	Buy	3.61	10,957	39,592	268,260	Jun 01 04:30 PM
ALSTODT LANCE	President, CEO, COB	May 26	Buy	3.52	2,700	9,494	178,621	May 27 10:23 AM
Broadrick Dale	10% Owner	May 26	Buy	3.51	4,950	17,364	259,303	May 31 05:18 PM
Broadrick Dale	10% Owner	May 26	Sale	3.44	2,000	6,876	257,303	May 31 05:18 PM
ALSTODT LANCE	President, CEO, COB	May 02	Buy	3.95	400	1,579	175,921	May 02 05:14 PM
Kristal Robert Eugene	Chief Financial Officer	Apr 08	Buy	5.71	7,600	43,396	7,600	Apr 11 10:47 AM
Broadrick Dale	10% Owner	Apr 06	Buy	5.66	2,500	14,150	254,353	Apr 08 04:23 PM
Broadrick Dale	10% Owner	Apr 05	Buy	5.71	46,000	262,640	251,853	Apr 07 04:15 PM
Broadrick Dale	10% Owner	Mar 31	Buy	4.72	10,700	50,488	316,972	Apr 01 04:54 PM
Broadrick Dale	10% Owner	Mar 29	Buy	5.12	5,000	25,600	306,272	Apr 01 04:54 PM
Broadrick Dale	10% Owner	Mar 21	Buy	4.35	10,000	43,500	205,853	Mar 29 04:52 PM
Broadrick Dale	10% Owner	Mar 09	Buy	4.00	11,875	47,500	195,853	Mar 29 04:52 PM
Broadrick Dale	10% Owner	Mar 08	Buy	4.00	8,125	32,500	183,978	Mar 29 04:52 PM
Broadrick Dale	10% Owner	Mar 07	Buy	4.43	24,392	108,057	175,853	Mar 29 04:52 PM
Broadrick Dale	10% Owner	Mar 04	Buy	5.51	3,800	20,938	301,272	Mar 29 04:52 PM
Broadrick Dale	10% Owner	Mar 03	Buy	5.47	47,648	260,635	297,472	Mar 29 04:52 PM
Broadrick Dale	10% Owner	Mar 02	Buy	5.61	47,840	268,382	249,824	Mar 29 04:52 PM
Broadrick Dale	10% Owner	Mar 01	Buy	5.55	2,270	12,598	201,984	Mar 29 04:52 PM
ALSTODT LANCE	President, CEO, COB	Jan 24	Buy	3.40	1,470	4,998	163,083	Jan 24 05:03 PM
ALSTODT LANCE	President, CEO, COB	Jan 05	Buy	3.85	2,000	7,700	161,613	Jan 05 04:52 PM
ALSTODT LANCE	President, CEO, COB	Dec 01	Buy	5.50	799	4,394	159,613	Dec 02 10:00 AM
ALSTODT LANCE	President, CEO, COB	Nov 23	Buy	6.00	2,500	15,000	158,814	Nov 23 05:15 PM
ALSTODT LANCE	President, CEO, COB	Nov 22	Buy	6.31	396	2,499	156,314	Nov 22 05:29 PM
Silva Francisco	VP of Research and Development	Nov 19	Buy	6.66	4,000	26,626	11,829	Nov 22 12:17 PM
ALSTODT LANCE	President, CEO, COB	Nov 16	Buy	6.71	4,500	30,201	155,918	Nov 16 06:07 PM
Silva Francisco	VP of Research and Development	Nov 16	Buy	6.73	7,826	52,632	7,829	Nov 16 05:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience